News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
61 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37191)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53928)
2023 (42568)
2024 (38486)
2025 (17535)
Month
January (2946)
February (2976)
March (2714)
April (2913)
May (3639)
June (2347)
Day
2 (202)
3 (126)
4 (116)
5 (124)
6 (51)
9 (127)
10 (95)
11 (131)
12 (128)
13 (61)
16 (159)
17 (116)
18 (142)
19 (71)
20 (36)
23 (191)
24 (140)
25 (137)
26 (113)
27 (81)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
Day
2
3
4
5
6
9
10
11
12
13
16
17
18
19
20
23
24
25
26
27
Press Releases
Vial Initiating Phase 1 Healthy Volunteer Trial of VIAL-TL1A-HLE, a Novel Subcutaneous Half-Life Extended Anti-TL1A Antibody for the Treatment of IBD and Other Inflammatory and Fibrotic Diseases
· VIAL-TL1A-HLE is a novel, subcutaneous mAb with proprietary half-life extension technology targeting TL1A for a potentially best-in-class treatment for IBD · Preclinical data support the potential for best-in-class dosing interval for patient convenience and efficacy among anti-TL1A therapies · A Phase 1 open-label study in Australia is initiating to evaluate safety, pharmacokinetics, and pharmacodynamic responses in healthy volunteers · Interim subcutaneous safety and pharmacokinetic data from healthy volunteers expected in H2 2025
June 13, 2025
·
1 min read
Press Releases
MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Congress Validating High Efficacy Observed in Pivotal ARES Study in Acute Graft-versus-Host Disease
June 13, 2025
·
6 min read
Press Releases
Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine
June 13, 2025
·
2 min read
Press Releases
U.S. Life Science Tools Market Size to Hit USD 156.51 Billion by 2034
June 13, 2025
·
1 min read
Press Releases
GMP Plasmid DNA Market Size to Surpass USD 608.57 Million at 9.34% CAGR by 2034
June 13, 2025
·
1 min read
Press Releases
InMed Appoints CBIZ as New Auditor in Connection with CBIZ’s Acquisition of Marcum’s Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA
June 13, 2025
·
5 min read
Press Releases
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
June 13, 2025
·
3 min read
Press Releases
Werewolf Therapeutics to Participate in the BIO International Convention
June 13, 2025
·
5 min read
Press Releases
Nona Biosciences and Visterra Partner to Advance Next-Generation Biotherapeutics for Immune-Mediated and Autoimmune Diseases
June 13, 2025
·
2 min read
Press Releases
AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®
June 13, 2025
·
4 min read
Previous
2 of 7
Next
